CETP and SGLT2 inhibitor combination therapy improves glycemic control.
medRxiv : the preprint server for health sciences(2023)
摘要
Our findings suggest that CETP inhibitors, which are currently in clinical trials to treat cardiovascular disease, can be repurposed to treat metabolic disease in a combination therapy approach with SGLT2 inhibitors.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要